Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

March 20, 2019

Bayer, Orion Seek Darolutamide’s Approval in Europe for Non-metastatic CRPC

News

Bayer and Orion have successfully submitted an application to the European Medicines Agency seeking the approval of darolutamide for men with non-metastatic castration-resistant prostate cancer (nmCRPC). The application follows promising results from the ARAMIS Phase 3 trial (NCT02200614), where ... Read more

March 6, 2019

Opdivo-Yervoy Combo Shows Signs of Activity in CRPC Patients with Metastases

News

A combination of Bristol-Myers Squibb’s immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) reduces tumor burden in castration-resistant prostate cancer patients whose tumors have spread, interim Phase 2 results show. Findings from the CheckMate 650 ... Read more

February 28, 2019

Leap’s DKN-01 Enters Testing in Metastatic Castration-resistant Prostate Cancers

News

Leap Therapeutics is launching a Phase 1/2 trial to study its lead candidate DKN-01, alone or in combination with chemotherapy, for the treatment of metastatic castration-resistant prostate cancer (CRPC) patients whose ... Read more

February 6, 2019

Precision Radiation Therapy to Treat Prostate Cancer Spread Safe for High-Risk Patients, Phase 2 Trial Finds

News

Prostate cancer patients at a high risk of tumor spreading can safely receive high-dose radiation therapy that targets both the prostate and neighboring pelvic lymph nodes, a Phase 2 trial ... Read more

January 30, 2019January 30, 2019

FDA Clears Phase 1 Trial of ARV-110 for Advanced Prostate Cancer

News

The U.S. Food and Drug Administration has signed off on Arvinas‘ first Phase 1 clinical trial to evaluate ARV-110 as a therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). The ... Read more

January 16, 2019

Coffee and Tea Intake Not Linked to Prostate Cancer Risk, According to Large European Study

News

Drinking tea or coffee, with or without caffeine, has no impact on the risk for prostate cancer, according to the results of a large European study. The study, “Coffee and ... Read more

January 10, 2019

Phase 2 Trial of Tomivosertib Begins Dosing Advanced Castration-resistant PC Patients

News

A Phase 2 clinical trial evaluating eFFECTOR Therapeutics’ investigational therapy tomivosertib (eFT508), for men with advanced castrate-resistant prostate cancer (CRPC) who failed to respond to androgen receptor signaling (ARS) inhibitors, has begun ... Read more

December 12, 2018

Phase 3 Trial Testing New Imaging Agent for Prostate Cancer Detection Doses First Patient

News

A Phase 3 trial evaluating Progenics Pharmaceuticals‘ new imaging agent to help detect prostate cancer recurrence has begun dosing participants. The agent, called PyL (18F-DCFPyl), is a tracing substance composed of the prostate ... Read more

December 6, 2018

New Imaging Agent Better at Detecting Signs of Prostate Cancer Recurrence, Study Reports

News

A new imaging agent for use in positron emission tomography (PET) is better than conventional imaging at detecting cancer location and spread in prostate cancer patients suspected of cancer recurrence, ... Read more

September 5, 2018

Higher Radiotherapy Doses But Fewer Treatment Sessions May Be Possible, Early Trial Data Suggest

News

Prostate cancer patients may benefit from a new form of radiation therapy that delivers larger doses per session but in a much shorter treatment course, and when used in combination ... Read more